The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1224-1229

  Knebel, William ^a   Davis Jr , John C ^a   Sanders, William D ^a   Fessler, Barri ^a   Yarboro, Cheryl ^a   Pucino, Frank ^a   Boumpas, Dimitrios T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMALARIAL AGENT; CORTICOSTEROID; FLUDARABINE; GOLD; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TISSUE DISTRIBUTION;

ADULT; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; REGRESSION ANALYSIS; VIDARABINE;

EID: 0031756149     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kingsley G, Panayi GS. Joint destruction in rheumatoid arthritis: biological basis. Clin Exp Rheumatol 1997;15(suppl 17):3-14.
2. Cash JM, Klippel JH. Second-line therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
3. Plunkett W, Gandhi V. Nucleoside analogs: cellular pharmacology, mechanism of action, and strategies for combination therapy. In: Cheson BD, Keating MJ, Plunkett W, eds. Nucleoside analogs in cancer therapy. New York: Marcel Dekker, 1997:1-36.
4. Sipe JC, Romine JS, Koziol JA, McMillan R, Zxyroff J, Beutler E. Cladribine in the treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13.
5. Tassiulas IO, Boumpas DT, Vaughan EM, et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy [abstr]. J Am Soc Nephrol 1996;7:1782.
6. Fessier BJ, Yarboro CH, Klippel JH, Hama N, Wilder RL, Boumpas DT. A pilot study of fludarabine in refractory rheumatoid arthritis [abstr]. Arthritis Rheum 1995;38:S282.
7. Smith OP, Hoffbrand AV, Buckley C. Fludarabine and psoriasis. N Engl J Med 1994;330:1540-1.
8. Eibschutz B, Baird SM, Weisman MH, et al. Oral 2-chlorodeoxyadenosine in psoriatic arthritis. Arthritis Rheum 1995;38:1604-9.
9. Davis JC, Klippel J, Boumpas D, Yarboro C, Larson A, Scott D. 2'chlorodeoxyadenosine (CdA) treatment in lupus nephritis [abstr]. Arthritis Rheum 1996;39:S245.
10. Tassiulas IO, Davis JC Jr, Fessier BJ, et al. Fludarabine in non-malignant disorders. In: Cheson BD, Keating MJ, Plunket W, eds. Nucleoside analogs in cancer therapy. New York: Marcel Dekker, 1997:383-414.
11. French Cooperative Group on Chronic Lymphocytic Leukemia. Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996;347:1432-8.
12. Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden T, Von Hoff DD. Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 1986;17: 277-80.
13. Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-Ara-A (9-β-D-Arabinofuranosyl-2-fluoroadenine) in cancer patients during phase 1 clinical investigation of fludarabine phosphate. Semin Oncol 1990;17:18-32.
14. Avramis VI, Champagne J, Sato J, et al. Pharmacology of fludarabine phosphate after a phase I/II trial by loading bolus and continuous infusion in pediatric patients. Cancer Res 1990;50:7226-31.
15. Felson D, Anderson J, Toers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
16. Kemena A, Fernandez M, Bauman J, Keating M, Plunkett W. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin Chim Acta 1991; 200:95-106.
17. D'Argenio DZ, Schumitzky A. ADAPT II user's guide. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1990.
18. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
19. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed., New York: Marcel Dekker, 1982.
20. Edworthy AF, Bloch D, McShane DJ, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9: 503-12.